



BRAWN



96D97

CIN NO.: L74899DL1985PLC022468

11th February, 2020

**The General Manager
The Department of Corporate Services,
BSE Limited, 25th Floor,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai- 400001**

BSE Scrip Code: 530207

Scrip Id: BRAWN

Sub: Outcome of Board Meeting and Submission of Un-audited Financial Results for the quarter and nine month ended 31.12.2019

Dear Sir/ Ma'am,

Pursuant to the Regulation 30 read with schedule III, Part A of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that a meeting of the Board of Directors of the company was held today i.e. 11th February, 2020 to consider and approve,

1. Standalone Unaudited Financial Results for the quarter and nine months ended December 31st, 2019.
2. Limited Review Report by the statutory Auditors of the company. The Board took note that the statutory auditors have expressed an unqualified and unmodified audit opinion.

The meeting of the Board of Directors commenced at 3:00 P.M. and concluded at 4:45 P.M.

Kindly take the same on record

For BRAWN BIOTECH LIMITED

Priyanka Sharma
for Brawn Biotech Limited

**Priyanka Sharma
Company Secretary & Compliance Officer
Membership No. A50385**

Encl: As above

BRAWN BIOTECH LTD.

(Formerly Known as Brawn Pharmaceuticals Ltd.)

...for better life

Regd. Office : 4B, Asaf Ali Road, II Floor, Delhi Stock Exchange Building, New Delhi 110002 IN Tel: 0124-4666152, 4222462,
Email: solution@brawnbiotech.com, Website : www.brawnbiotech.com

Export Office : 4B, Asaf Ali Road, II Floor, Delhi Stock Exchange Building, New Delhi 110002 IN Tel: 011-23275208 Fax : 011-23275208

Corporate Office : Plot No. - 30, Sector - 33, Near Hero Honda Factory, Gurugram (Haryana) 122001, Tel.: 0124-4666152, 4222462
Email: solution@brawnbiotech.com

Works : 13, Industrial Area, N.I.T., Faridabad -121001 (Haryana) Tel : +91 - 8010416849/48



BRAWN

CIN NO.: L74899DL1985PLC022468

BRAWN BIOTECH LIMITED							
REGD. OFFICE: 4B, Asaf Ali Road, II Floor, Delhi Stock Exchange Building, New Delhi 110002							
STATEMENT OF STANDALONE UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31st DECEMBER 2019							
						Rs. In Lacs	
Sr. No.	Particulars	Quarter ended			Nine Months ended		Year Ended
		3 months ended	3 months ended	3 months ended	9 months ended	9 months ended	Accounting Year ended
		31.12.2019	30.09.2019	31.12.2018	31.12.2019	31.12.2018	31.03.2019
		Un-audited	Un-audited	Audited	Un-audited	Un-audited	Audited
1	Revenue from operations						
	Revenue from operations	1322.29	1,187.93	2,123.36	4,294.97	4,975.45	6,517.90
	Other Income	1.72	3.34	0.16	6.21	14.10	73.78
	Total Revenue	1,324.01	1,191.27	2,123.52	4,301.18	4,989.55	6,591.68
2	Expenses						
a	Cost of material consumed	-	-	-	-	-	-
b	Purchase of stock-in-trade	1191.42	1,011.81	1,933.27	3,802.90	4,472.65	5,848.92
c	Change in inventories of finished goods, work in progress and stock in trade	(32.07)	24.00	2.34	(25.11)	1.70	0.90
d	Employee Benefit expenses	116.11	55.04	104.73	224.01	217.42	302.49
e	Depreciation and amortisation expenses	0.96	0.80	0.81	2.55	2.41	3.20
f	Finance Cost	0.52	1.84	2.18	3.28	3.97	6.14
g	Other expenses	41.83	55.22	43.75	173.31	146.88	249.50
	Total Expenses	1,318.77	1,148.72	2,087.08	4,180.94	4,845.03	6,411.15
3	Profit from Operation before Other Income, exceptional and extra-ordinary Items (1-2)	5.24	42.55	36.44	120.24	144.53	180.54
4	Other Income	-	-	-	-	-	-
5	Profit from ordinary activities before exceptional items (3-4)	5.24	42.55	36.44	120.24	144.53	180.54
6	Exceptional Items	-	-	-	-	-	-
7	Profit from ordinary activities before tax (5-6)	5.24	42.55	36.44	120.24	144.53	180.54
8	Tax Expenses	1.56	0.55	10.23	28.84	41.72	47.24
9	Profit (Loss) for the period from continuing operations (7-8)	3.68	34.01	26.21	91.40	102.81	133.29
10	Profit/(loss) from discontinuing operations	-	-	-	-	-	-
11	Tax expense of discontinuing operations	-	-	-	-	-	-
12	Profit/(loss) from Discontinuing operations (after tax) (10-11)	-	-	-	-	-	-
13	Profit (Loss) for the period (9+12)	3.68	34.01	26.21	91.40	102.81	133.29
14	Other Comprehensive Income	0.96	(2.93)	0.33	(7.07)	5.45	5.53
	Total Comprehensive Income	4.64	31.07	26.54	84.33	108.26	138.82
15	Details of equity share capital	300.03	300.03	300.03	300.03	300.03	300.03
	Paid-up equity share capital						
	Face value of equity share capital						
16	Reserve excluding Revaluation Reserve						
17	Earnings per share						
i	Basic earnings per share	0.15	1.04	0.88	2.81	3.61	4.63
ii	Diluted earnings per share	0.15	1.04	0.88	2.81	3.61	4.63

NOTES :-

- Results for the quarter ended on 31st December, 2019 were reviewed by the Audit committee and then approved by the Board of Directors at their meeting held on 11th February, 2020.
- The Statutory Auditors carried out the limited review for quarter ended 31st December, 2019. The management has exercised necessary due diligence to ensure that the financial results provided a true and fair view of its affairs.
- The above results have been prepared in compliance with the recognition and measurement principles of the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS), as amended by the Companies (Indian Accounting Standards) (Amendment) Rules, 2016 prescribed under Section 133 of the Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable.
- The Company is engaged primarily in the business of Pharmaceuticals. Accordingly, there is no separate reportable segments as per Ind-AS 108 dealing with Operating Segments.
- The above Standalone Un-audited Financial Results for the quarter ended on 31-12-2019 are available on company's website www.brawnbiotech.com and BSE website www.bseindia.com.
- Figures for the quarter ended 31st December 2019 are the differences between the figures for the nine months ended 31st December 2019 and six months ended 30th September 2019.
- Previous year / period figures have been regrouped / rearranged, wherever necessary to make them comparable with the current period figures.

For and on behalf of Board
For Brawn Biotech Limited
For Brawn Biotech Ltd.
Brij Raj Gupta
Managing Director
DIN NO. 00974969
Date: 11.02.2020
Place: Delhi Director

BRAWN BIOTECH LTD.

(Formerly Known as Brawn Pharmaceuticals Ltd.)

... for better life

Regd. Office : 4B, Asaf Ali Road, II Floor, Delhi Stock Exchange Building, New Delhi 110002 IN Tel: 0124-4666152, 4222462,
Email: solution@brawnbiotech.com, Website : www.brawnbiotech.com

Export Office : 4B, Asaf Ali Road, II Floor, Delhi Stock Exchange Building, New Delhi 110002 IN Tel: 011-23275208 Fax : 011-23275208

Corporate Office : Plot No. - 30, Sector - 33 , Near Hero Honda Factory, Gurugram (Haryana) 122001 , Tel.: 0124-4666152, 4222462
Email: solution@brawnbiotech.com

Works : 13, Industrial Area, N.I.T., Faridabad -121001 (Haryana) Tel.: +91 - 8010416849/48



To,
The Board of Directors of
Brawn Biotech Limited

RAJIV UDAI & ASSOCIATES
CHARTERED ACCOUNTANTS

We have reviewed the accompanying statement of unaudited financial results of Brawn Biotech Limited for the period ended 31st December 2019. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Our conclusion is not modified in respect of this matter.

For Rajiv Udai & Associates
Chartered Accountants
Firm Registration No. 018764N


Rajeev Jain
Partner

Membership No. 099767

UDIN: 20099767 AAAACC3155



Place: Delhi

Date: 11-02-2020